Camens Sophie, Liu Sha, Hon Karen, Bouras George Spyro, Psaltis Alkis James, Wormald Peter-John, Vreugde Sarah
Department of Health and Medical Sciences-Surgery, The University of Adelaide, Adelaide 5000, Australia.
Department of Surgery-Otolaryngology Head and Neck Surgery, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville South 5011, Australia.
Microorganisms. 2021 Sep 21;9(9):2001. doi: 10.3390/microorganisms9092001.
A () airway infection is one of the predominant causes contributing to the high morbidity and mortality rates in cystic fibrosis (CF) patients. The emergence of antibiotic resistant strains has led to an urgent need for new therapeutic approaches. Bacteriophages (phages) are viruses that can infect and lyse specific bacteria, providing a potential alternative approach in targeting antibiotic-resistant strains. We aim to isolate and characterise novel phages for combination in a cocktail to kill One particular phage, PA4, could lyse 14/20 clinical isolates as observed through spot assays. This phage could significantly reduce the growth of bacteria in vitro, as determined through planktonic adsorption and inhibition assays as well as crystal violet- and LIVE/DEAD-stained biofilm assays. A morphological and genomic analysis revealed that PA4 belongs to the Myoviridae family and contained 66,450 bp. The broad infectivity profile, good stability in various pH and temperature conditions, lytic ability and the absence of the absences of antibiotic resistance, toxic and lysogenic genes suggest that PA4 is a good candidate for clinical grade use. Overall, phage therapy represents a promising alternative treatment option to antibiotics when treating a infection.
A（）气道感染是导致囊性纤维化（CF）患者高发病率和高死亡率的主要原因之一。抗生素耐药菌株的出现迫切需要新的治疗方法。噬菌体是能够感染并裂解特定细菌的病毒，为靶向抗生素耐药菌株提供了一种潜在的替代方法。我们旨在分离和鉴定新型噬菌体，将其组合成鸡尾酒制剂以杀死（）。通过点滴试验观察到，一种特定的噬菌体PA4能够裂解20株临床分离株中的14株。通过浮游吸附和抑制试验以及结晶紫染色和活/死染色生物膜试验确定，这种噬菌体能够显著降低体外细菌的生长。形态学和基因组分析表明，PA4属于肌尾噬菌体科，基因组大小为66,450 bp。广泛的感染谱、在各种pH和温度条件下的良好稳定性、裂解能力以及不存在抗生素耐药性、毒性和溶原性基因，表明PA4是临床级应用的良好候选者。总体而言，在治疗（）感染时，噬菌体疗法是一种有前景的抗生素替代治疗选择。
